,0
symbol,FGEN
price,41.75
beta,1.68382
volAvg,726992
mktCap,3799696900
lastDiv,0.0
range,22.65-51.56
changes,0.74
companyName,FibroGen Inc
currency,USD
cik,0000921299
isin,US31572Q8087
cusip,31572Q808
exchange,Nasdaq Global Select
exchangeShortName,NASDAQ
industry,Biotechnology
website,http://www.fibrogen.com
description,"FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. The company is headquartered in San Francisco, California and currently employs 461 full-time employees. The firm is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Companyâ€™s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The firm has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure."
ceo,Mr. Enrique Conterno
sector,Healthcare
country,US
fullTimeEmployees,531
phone,14159781200
address,409 Illinois St
city,San Francisco
state,CALIFORNIA
zip,
dcfDiff,
dcf,46.5575
image,https://financialmodelingprep.com/image-stock/FGEN.jpg
ipoDate,2014-11-14
defaultImage,True
